July 21, 2016
Metaclipse Therapeutics receives $2.4 million grant for breast cancer vaccine
By Ellie Hensley, Atlanta Business Chronicle
A team of Emory University and Atlanta-based Metaclipse Therapeutics Corp. researchers landed a $2.4 million grant from the National Institutes of Healthand National Cancer Institute.
The five-year grant will be used to develop new cancer vaccine immunotherapies for patients with triple-negative breast cancer (TNBC).
TBNC is very hard to treat because it doesn't present any defined targets for drugs or vaccines to attack, and five-year survival rates are lower for it than other types of breast cancer. The disease is more common in young African-American women.
The researchers are developing a vaccine using tumor membrane vesicles derived from the patient's own tumor.
NIH previously gave Metaclipse a grant to study the vaccine technology in a mouse model of TNBC. It has also received grants from the Georgia Research Alliance Venture Lab program and the Coulter Foundation.
